comparemela.com

Latest Breaking News On - Philip stellarex - Page 1 : comparemela.com

Philips Announces Positive Three-Year Clinical Research Results from its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) Clinical Trial

Philips Announces Positive Three-year Clinical Research Results from its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) Clinical Trial

For below-the-knee arterial dissection repair following balloon angioplasty, innovative medical technology shows sustained treatment effect and positive impact on quality of life for patients with critical limb ischemia (CLI)  

ECG Flags COVID Mortality; ICDs & Depression; Pre-Conception Test for Heart Disease?

Journal of the American College of Cardiology) Stroke survivors trying to regain arm function in rehabilitation found incremental improvement with vagus nerve stimulation in the VNS-REHAB trial. ( The Lancet) The American College of Physicians released a guideline on the use of point-of-care ultrasound for patients with acute dyspnea. A theory posits that dual SGLT1 and SGLT2 inhibition could improve cardiovascular outcomes for people with diabetes. ( Circulation) Philips Stellarex paclitaxel drug-coated balloon did not increase deaths at 5 years over percutaneous transluminal angioplasty in a 600-patient meta-analysis supporting its safety. Clotting drug tranexamic acid did not raise complication rates for high-risk patients undergoing orthopedic surgeries. (

Koninklijke Philips N V (PHG) Q4 2020 Earnings Call Transcript

Operator Welcome to the Royal Philips Fourth Quarter and Full Year 2020 Results Conference Call on Monday, January 25, 2021. During the call hosted by Mr. Frans van Houten, CEO; and Mr. Abhijit Bhattacharya, all participants will be in a listen-only mode. [Operator Instructions] I will now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir. Leandro Mazzoni Head of Investor Relations Good morning, ladies and gentlemen. Welcome to Philips fourth quarter and full year 2020 results conference call. I m here with our CEO, Frans van Houten; and our CFO, Abhijit Bhattacharya. On today s call, Frans will take you through our strategic and financial highlights for the period. Abhijit will then provide more detail on the financial performance. And after that, we will take your questions.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.